Evidence map›Paper›PMID 38176414›Full record

ArticleMolecular cell2024

Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma.

Damon A Hofman, Jorge Ruiz-Orera, Ian Yannuzzi, Rakesh Murugesan, Adam Brown, Karl R Clauser, Alexandra L Condurat, Jip T van Dinter, Sem A G Engels, Amy Goodale and 14 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
14.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 61 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Elucidating the Localization and Interactome of Mitochondrial Microproteins.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  11. Microproteins: Uncovering Hidden Layers of the Proteome.Methods in molecular biology (Clifton, N.J.) · 2026
    Review
  12. Review
  13. Review
  14. Non-coding RNA · 2025
    Review
  15. Article
  16. A pan-cancer atlas of therapeutic T cell targets.bioRxiv : the preprint server for biology · 2025
    Article
  17. Article
  18. Eukaryotic Microproteins.Annual review of biochemistry · 2025
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 9 institutions in 3 countries.

Damon A HofmanPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.
Jorge Ruiz-OreraCardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany.
Ian YannuzziBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Rakesh MurugesanBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Adam BrownBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Karl R ClauserBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Alexandra L ConduratBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Jip T van DinterPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.
Sem A G EngelsPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.
Amy GoodaleBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Jasper van der LugtPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.
Tanaz AbidBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Li WangBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Kevin N ZhouDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Jayne VogelzangDepartment of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02215, USA.
Keith L LigonDepartment of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02215, USA; Department of Pathology, Boston Children's Hospital, Boston MA 02115, USA.
Timothy N PhoenixDivision of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45229, USA.
Jennifer A RothBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
David E RootBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Norbert HubnerCardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany; Charité-Universitätsmedizin, 10117 Berlin, Germany; German Centre for Cardiovascular Research, Partner Site Berlin, 13347 Berlin, Germany.
Todd R GolubBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.
Pratiti BandopadhayayBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.
Sebastiaan van HeeschPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands. Electronic address: s.vanheesch@prinsesmaximacentrum.nl.
John R PrensnerDepartment of Pediatrics, Division of Pediatric Hematology/Oncology and Biological Chemistry, University of Michigan Medical School, Ann Arbor, MI 48109, USA. Electronic address: prensner@umich.edu.
Broad Institute · USPrincess Máxima Center · NLBoston Children's Hospital · USDana-Farber Cancer Institute · USMax Delbrück Center · DEBrigham and Women's Hospital · USHarvard University · USUniversity of Cincinnati Medical Center · USUniversity of Michigan · US

Funding

Making cancer precision medicine real: bottlenecks and opportunitiesR35CA242457 · NCI · BROAD INSTITUTE, INC. · PI GOLUB, TODD R. · 2019 to 2025
$6.9M
Deciphering non-canonical translation in high risk medulloblastomaK08CA263552 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI John Prensner · 2022 to 2026
$1.2M
NCI NIH HHS K08 CA263552NCI NIH HHS R35 CA242457
6 · The paper itself

Abstract

A hallmark of high-risk childhood medulloblastoma is the dysregulation of RNA translation. Currently, it is unknown whether medulloblastoma dysregulates the translation of putatively oncogenic non-canonical open reading frames (ORFs). To address this question, we performed ribosome profiling of 32 medulloblastoma tissues and cell lines and observed widespread non-canonical ORF translation. We then developed a stepwise approach using multiple CRISPR-Cas9 screens to elucidate non-canonical ORFs and putative microproteins implicated in medulloblastoma cell survival. We determined that multiple lncRNA-ORFs and upstream ORFs (uORFs) exhibited selective functionality independent of main coding sequences. A microprotein encoded by one of these ORFs, ASNSD1-uORF or ASDURF, was upregulated, associated with MYC-family oncogenes, and promoted medulloblastoma cell survival through engagement with the prefoldin-like chaperone complex. Our findings underscore the fundamental importance of non-canonical ORF translation in medulloblastoma and provide a rationale to include these ORFs in future studies seeking to define new cancer targets.

Indexed as

Cerebellar NeoplasmsMedulloblastomaCell SurvivalHumansOpen Reading FramesProtein BiosynthesiscancerCRISPRgene dependencylncRNAsmedulloblastomanon-canonical ORFsRibo-seqtranslational regulationuORF

Identifiers

PMID38176414
PMCPMC10872554
OpenAlexW4390535824

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.